We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Store » Webinar Recordings » FDA’s Big 5 Challenges - Webinar CD/Transcript

Other Options

Audio CD/Transcript - July 13, 2017

$287.00

Audio CD/Transcript - July 13, 2017

$258.00

Audio CD/Transcript - July 13, 2017

$244.00

Audio CD/Transcript - July 13, 2017

$230.00

Audio CD/Transcript - July 13, 2017

$215.00

FDA’s Big 5 Challenges - Webinar CD/Transcript

$287.00
Webinar Recordings

Product Details

FDA’s Big 5 Challenges: Agency Tackles Botox, Cannabis, Opioids, Tobacco Intended Use, Right-to-Try

The FDA likely will break new ground this year, posing extraordinary regulatory challenges to Rx, food and tobacco interests.

Botox. Cannabis. Opioids. Tobacco intended use. State right-to-try initiatives. How will the FDA tackle these hot potatoes? How will agency actions affect you?

Here’s your opportunity to peek behind the agency’s closed doors as it makes ready to enter uncharted territory. Join us for a first-ever look at the 5 hot-button issues that could affect the FDA’s direction — and your future:

  • Botox approvals:  Black box warnings, patents, scams, Botox® parties, legal implications, state actions ...
  • Marijuana regulation: Likelihood of regulation as a drug, “medical marijuana” and the FDA, synthetic marijuana regulation, state and local actions ...
  • Opioid Task Force:  How its actions could affect Rx drugmakers, potential new regulatory initiatives ...
  • The Intended Use Rule: How it might change during the Gottlieb tenure ...
  • Right -to-Try Movement: Gaining momentum or losing steam? And what will be the impact on pharmaceutical regulatory and quality operations?

Lawyer and author Roseann B. Termini Esq. is your guide. With more than 30 years of expertise in FDA regulatory areas including direct-to-consumer advertising and corporate accountability, she’ll fill you in on current FDA thinking and trends.

It’s a first-ever opportunity to prepare in advance for an extraordinary regulatory year. Don’t miss it.

  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing